奥翔药业 (603229.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

27.1x

Market Cap

CNY 6.59B

MomentumView details →

1D Return

−1.98%

YTD Return

−21.47%

RSI (14)

44.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

27.1x

Market Cap

CNY 6.59B

RSI (14)

44.4

MomentumView details →

1D Return

−1.98%

YTD Return

−21.47%

ProfitabilityView details →

Gross Margin

54.06%

Net Margin

13.59%

EBITDA Margin

26.95%

ROE (TTM)

4.56%

ROA (TTM)

3.42%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

−0.78%

EPS YoY

−48.75%

FCF YoY

−9.19%

Revenue CAGR 3Y

+1.22%

EPS CAGR 3Y

−26.92%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.20x

Current Ratio

2.64x

Quick Ratio

2.12x

Div Yield

0.82%

Div Rate

CNY 0.06

Div Growth 1Y

−36.00%

Financials snapshotView financials →

Revenue (TTM)

794.80M

Net Income (TTM)

108.03M

Op. CF (TTM)

120.43M

Latest newsMore news →

Aoxiang Pharmaceutical announced its first-half 2026 results with revenue of 468 million yuan, down 2.96% year-on-year, and net profit attributable to shareholders of 120 million yuan, down 29.23% year-on-year.7d ago

Aoxiang Pharmaceutical's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical received drug registration certificates from China's National Medical Products Administration for ruxolitinib phosphate tablets in 5mg, 15mg, and 20mg strengths, deemed equivalent to passing generic consistency evaluation.14d ago

Similar companies

CG Oncology, Inc. Common stockCGON Mirum Pharmaceuticals, Inc.MIRM 艾迪药业688488.SH Arcellx, Inc.ACLX Scholar Rock Holding CorporationSRRK 昊海生科688366.SH Find similar companies →

Latest newsMore news →

Aoxiang Pharmaceutical announced its first-half 2026 results with revenue of 468 million yuan, down 2.96% year-on-year, and net profit attributable to shareholders of 120 million yuan, down 29.23% year-on-year.7d ago Aoxiang Pharmaceutical's wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical received drug registration certificates from China's National Medical Products Administration for ruxolitinib phosphate tablets in 5mg, 15mg, and 20mg strengths, deemed equivalent to passing generic consistency evaluation.14d ago